Genetic Signatures expands its Board of Directors with the appointment of Pat Noland
Sydney, Australia 30th October 2014
Genetic Signatures Ltd today announced the appointment of Pat Noland to its Board of Directors in the capacity of non-executive director.
Mr. Noland currently serves as Chief Executive Officer of StrataDx, a leading provider of high-quality pathology services in the dermatology, urology, podiatry, oral pathology, gastroenterology, and gynecology segments.
Mr. Noland joined StrataDx after 17 years at the $5 billion clinical-laboratory company, Laboratory Corporation of America (LabCorp). Mr. Noland was most recently senior vice president responsible for developing and implementing LabCorp’s hospital strategy. Previously, Mr. Noland held full P&L responsibility for DIANON Systems, LabCorp’s anatomic pathology business, as well as a series of other senior leadership roles.
Pat Noland has said “I am pleased to be joining the Genetic Signatures board during this significant period in the company’s history. They are uniquely positioned to provide the tools that will assist pathology laboratories to make the move from traditional to molecular diagnostic methods.”
“The addition of Pat Noland to the board strengthens our position as a pioneer in molecular diagnostics. His knowledge of the needs of U.S. pathology providers complement the skills and knowledge of the existing team.” said Dr John Melki, CEO of Genetic Signatures.
About Genetic Signatures: Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, 3Base™. Genetic Signatures has developed and commercialised a suite of real time PCR based products for the routine detection of infectious diseases. The Company’s proprietary technology provides hospital and pathology laboratories with the molecular tools to screen for a wide array of infectious pathogens in a rapid high-throughput environment.